Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma - 30/05/24

Doi : 10.1016/j.clinre.2024.102390

Jianpeng Wang ^1,^⁎ , Ping Xiao ², Xishan Li ³, Wenyu Wu ¹, Degang Shi ¹, Wei Lin ², Zuchang Wu ²
¹ Target and Interventional Radiology Department of Oncology, First People's Hospital of Foshan, Foshan, China
² Department of Experimental Research, First People's Hospital of Foshan, Foshan, China
³ Department of Interventional Radiology, Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China

^⁎Corresponding author. Jianpeng Wang, Target and Interventional Radiology department of Oncology, First People's Hospital of Foshan, China, No. 81 of Lingnandadao North, Foshan 528000, Guangdong Province, ChinaTarget and Interventional Radiology department of OncologyFirst People's Hospital of FoshanChina, No. 81 of Lingnandadao NorthFoshanGuangdong Province528000China

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Thursday 30 May 2024
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Highlights

•	Circulating immune cells have shown to have a correlation with the response to immunotherapy in hepatocellular carcinoma patients.
•	Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.
•	The number of circulating NK cells increased when patients with hepatocellular carcinoma received Lenvatinib in combination with ICIs.
•	A low level of circulating CD3⁺ T and CD4⁺ T cells was associated with a poor prognosis.

Le texte complet de cet article est disponible en PDF.

Abstract

Purpose: This study investigated the dynamic changes in peripheral immune cells following immune checkpoint inhibitors (ICIs), tyrosine kinase inhibitors (TKIs), and interventional therapy in hepatocellular carcinoma (HCC).

Methods: HCC patients undergoing transarterial chemoembolization (TACE), TKI, and ICI treatment were included in the treatment group. Peripheral blood samples were collected from these patients before each cycle of PD-1 blockade treatment. Flow cytometry analysis was conducted to assess the composition of peripheral immune cells and identify PD-1-expressing T cells.

Results: The treatment group showed a median time-to-tumor progression (TTP) of 8 months and an overall survival (OS) of 19 months. In comparison, the control group had 6 months and 15 months respectively. These differences were statistically significant (P=0.029 for TTP and P=0.020 for OS). In HCC patients receiving Lenvatinib, more circulating natural killer (NK) cells were noted. After 1-2 cycles of PD-1 antibody treatment, a general decline in the proportion of circulating PD-1⁺T cells was found, indicating individual variations in response.

Conclusion: Circulating immune cells have the potential to serve as indicators of the response to immunotherapy, providing a means to monitor dynamic changes and optimize treatment for HCC.

Le texte complet de cet article est disponible en PDF.

Keywords : Circulating immune cells, Immunotherapy, Hepatocellular carcinoma